Plevin Rebecca, Callcut Rachael
Department of Surgery, University of California San Francisco, San Francisco, California, USA.
Trauma Surg Acute Care Open. 2017 Sep 7;2(1):e000088. doi: 10.1136/tsaco-2017-000088. eCollection 2017.
Sepsis remains a highly lethal entity resulting in more than 200 000 deaths in the USA each year. The in-hospital mortality approaches 30% despite advances in critical care during the last several decades. The direct health care costs in the USA exceed $24 billion dollars annually and continue to escalate each year especially as the population ages. The Surviving Sepsis Campaign published their initial clinical practice guidelines for the management of severe sepsis and septic shock in 2004. Updated versions were published in 2008, 2012 and most recently in 2016 following the convening of the Third International Consensus Definitions Task Force. This task force was convened by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine to address prior criticisms of the multiple definitions used clinically for sepsis-related illnesses. In the 2016 guidelines, sepsis is redefined by the taskforce as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In addition to using the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score to more rapidly identify patients with sepsis, the task force also proposed a novel scoring system to rapidly screen for patients outside the ICU who are at risk of developing sepsis: the 'quickSOFA' (qSOFA) score. To date, the largest reductions in mortality have been associated with early identification of sepsis, initiation of a 3-hour care bundle and rapid administration of broad-spectrum antibiotics. The lack of progress in mortality reduction in sepsis treatment despite extraordinary investment of research resources underscores the variability in patients with sepsis. No single solution is likely to be universally beneficial, and sepsis continues to be an entity that should receive high priority for the development of precision health approaches for treatment.
脓毒症仍然是一种致死率很高的病症,在美国每年导致超过20万人死亡。尽管在过去几十年重症监护方面取得了进展,但院内死亡率仍接近30%。美国每年的直接医疗费用超过240亿美元,并且随着人口老龄化每年持续攀升。拯救脓毒症运动于2004年发布了其关于严重脓毒症和脓毒性休克管理的初始临床实践指南。2008年、2012年以及最近在2016年第三次国际共识定义特别工作组召开会议后发布了更新版本。该特别工作组由危重病医学会和欧洲重症监护医学会召集,以回应此前对临床上用于脓毒症相关疾病的多种定义的批评。在2016年的指南中,特别工作组将脓毒症重新定义为由宿主对感染的反应失调引起的危及生命的器官功能障碍。除了使用序贯[脓毒症相关]器官衰竭评估(SOFA)评分来更快地识别脓毒症患者外,特别工作组还提出了一种新的评分系统,用于快速筛查重症监护病房外有发生脓毒症风险的患者:“快速SOFA”(qSOFA)评分。迄今为止,死亡率的最大降幅与脓毒症的早期识别、启动3小时护理集束以及快速给予广谱抗生素有关。尽管投入了大量研究资源,但脓毒症治疗在降低死亡率方面仍缺乏进展,这突出了脓毒症患者的个体差异。没有单一的解决方案可能对所有人都普遍有益,脓毒症仍然是一个在精准医疗治疗方法开发中应高度优先考虑的病症。